JP7169429B2 - ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体 - Google Patents

ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体 Download PDF

Info

Publication number
JP7169429B2
JP7169429B2 JP2021507445A JP2021507445A JP7169429B2 JP 7169429 B2 JP7169429 B2 JP 7169429B2 JP 2021507445 A JP2021507445 A JP 2021507445A JP 2021507445 A JP2021507445 A JP 2021507445A JP 7169429 B2 JP7169429 B2 JP 7169429B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
nhc
heterocyclyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021507445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535904A5 (cg-RX-API-DMAC7.html
JP2021535904A (ja
Inventor
スティーブン イー． アマン，
エリザベス エム． ベーコン，
ジェディミナス ジェイ． ブリズジス，
エルバート チン，
チェンフン チョウ，
ジェロミー ジェイ． コッテル，
マリリン エス． エンダクウェ，
ジェイムズ ジー． テイラー，
ネイサン イー． ライト，
ゼン－ユー ヤン，
シェイラ エム． ジプフェル，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2021535904A publication Critical patent/JP2021535904A/ja
Priority to JP2022109092A priority Critical patent/JP2022130716A/ja
Publication of JP2021535904A5 publication Critical patent/JP2021535904A5/ja
Application granted granted Critical
Publication of JP7169429B2 publication Critical patent/JP7169429B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2021507445A 2018-08-13 2019-08-13 ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体 Active JP7169429B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022109092A JP2022130716A (ja) 2018-08-13 2022-07-06 ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862718273P 2018-08-13 2018-08-13
US62/718,273 2018-08-13
PCT/US2019/046380 WO2020036979A1 (en) 2018-08-13 2019-08-13 Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022109092A Division JP2022130716A (ja) 2018-08-13 2022-07-06 ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体

Publications (3)

Publication Number Publication Date
JP2021535904A JP2021535904A (ja) 2021-12-23
JP2021535904A5 JP2021535904A5 (cg-RX-API-DMAC7.html) 2022-07-14
JP7169429B2 true JP7169429B2 (ja) 2022-11-10

Family

ID=67777432

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021507445A Active JP7169429B2 (ja) 2018-08-13 2019-08-13 ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体
JP2022109092A Withdrawn JP2022130716A (ja) 2018-08-13 2022-07-06 ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022109092A Withdrawn JP2022130716A (ja) 2018-08-13 2022-07-06 ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体

Country Status (9)

Country Link
US (1) US11572362B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837012A1 (cg-RX-API-DMAC7.html)
JP (2) JP7169429B2 (cg-RX-API-DMAC7.html)
KR (1) KR102660255B1 (cg-RX-API-DMAC7.html)
CN (1) CN112566697B (cg-RX-API-DMAC7.html)
AU (2) AU2019321424B2 (cg-RX-API-DMAC7.html)
CA (1) CA3105795C (cg-RX-API-DMAC7.html)
TW (1) TWI797366B (cg-RX-API-DMAC7.html)
WO (1) WO2020036979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022007376A (es) 2019-12-20 2022-09-02 Tenaya Therapeutics Inc Fluoroalqull-oxadiazoles y sus usos.
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210036A1 (en) 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
WO2018152368A1 (en) 2017-02-16 2018-08-23 Gilead Sciences, Inc. Pyrrolo [1,2-b] pyridazine derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
US9624246B2 (en) 2015-02-06 2017-04-18 Merck Patent Gmbh Pyridazinone macrocycles as IRAK inhibitors and uses thereof
EP3313840B1 (en) 2015-06-24 2019-07-24 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210036A1 (en) 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
WO2018152368A1 (en) 2017-02-16 2018-08-23 Gilead Sciences, Inc. Pyrrolo [1,2-b] pyridazine derivatives
JP2020507601A (ja) 2017-02-16 2020-03-12 ギリアード サイエンシーズ， インコーポレイテッド ピロロ［１，２−ｂ］ピリダジン誘導体
JP6924267B2 (ja) 2017-02-16 2021-08-25 ギリアード サイエンシーズ， インコーポレイテッド ピロロ［１，２−ｂ］ピリダジン誘導体

Also Published As

Publication number Publication date
CA3105795A1 (en) 2020-02-20
CA3105795C (en) 2024-01-16
EP3837012A1 (en) 2021-06-23
TWI797366B (zh) 2023-04-01
US20200071333A1 (en) 2020-03-05
AU2019321424B2 (en) 2022-07-14
AU2022204399A1 (en) 2022-07-14
WO2020036979A1 (en) 2020-02-20
KR20210044819A (ko) 2021-04-23
TW202021966A (zh) 2020-06-16
CN112566697B (zh) 2024-04-16
CN112566697A (zh) 2021-03-26
JP2022130716A (ja) 2022-09-06
JP2021535904A (ja) 2021-12-23
KR102660255B1 (ko) 2024-04-25
AU2019321424A1 (en) 2021-01-28
US11572362B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
TWI733982B (zh) 吡咯并[1,2-b]嗒衍生物
JP7216189B2 (ja) チアジアゾールｉｒａｋ４阻害剤
JP2022130716A (ja) ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体
JP2023002695A (ja) ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体
HK40045601A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
HK40045601B (zh) 作为irak4抑制剂的吡咯并[1，2-b]哒嗪衍生物
HK40045605A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
HK40019121B (en) Pyrrolo [1,2-b]pyridazine derivatives
HK40019121A (en) Pyrrolo [1,2-b]pyridazine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220406

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220706

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221028

R150 Certificate of patent or registration of utility model

Ref document number: 7169429

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250